Olink

Olink®
Part of Thermo Fisher Scientific

Features of acute COVID-19 associated with post-acute sequelae of SARS-CoV-2 phenotypes: results from the IMPACC study

Nature Communications, 2024

Ozonoff A., Jayavelu N., Liu S., Melamed E., Milliren C., Qi J., Geng L., McComsey G., Cairns C., Baden L., Schaenman J., Shaw A., Samaha H., Seyfert-Margolis V., Krammer F., Rosen L., Steen H., Syphurs C., Dandekar R., Shannon C., Sekaly R., Ehrlich L., Corry D., Kheradmand F., Atkinson M., Brakenridge S., Higuita N., Metcalf J., Hough C., Messer W., Pulendran B., Nadeau K., Davis M., Sesma A., Simon V., van Bakel H., Kim-Schulze S., Hafler D., Levy O., Kraft M., Bime C., Haddad E., Calfee C., Erle D., Langelier C., Eckalbar W., Bosinger S., McEnaney K., Barton B., Lentucci C., Saluvan M., Chang A., Hoch A., Albert M., Shaheen T., Kho A., Thomas S., Chen J., Murphy M., Cooney M., Hayati A., Bryant R., Abraham J., Presnell S., Jancsyk T., Maguire C., Lee B., Fourati S., Esserman D., Guan L., Gygi J., Pawar S., Brito A., Fragiadakis G., Patel R., Tebbutt S., Overton J., Vita R., Westendorf K., Thyagarajan R., Rousseau J., Wylie D., Triplett T., Kojic E., Chinthrajah S., Ahuja N., Rogers A., Artandi M., Yendewa G., Powell D., Kim J., Simmons B., Goonewardene I., Smith C., Martens M., Sherman A., Walsh S., Issa N., Salehi-Rad R., Dela Cruz C., Farhadian S., Iwasaki A., Ko A., Anderson E., Mehta A., Sevransky J., Leligdowicz A., Matthay M., Singer J., Kangelaris K., Hendrickson C., Krummel M., Woodruff P., Anderson M., Guirgis F., Drevets D., Brown B., Siegel S., Lu Z., Mosier J., Kimura H., Khor B., Rahman A., Stadlbauer D., Dutta J., Gonzalez-Reiche A., van de Guchte A., Carreño J., Singh G., Raskin A., Tcheou J., Bielak D., Kawabata H., Xie H., Kelly G., Patel M., Nie K., Yellin T., Fried M., Sullivan L., Morris S., Sieg S., van Zalm P., Fatou B., Mendez K., Lasky-Su J., Hutton S., Michelotti G., Wong K., Jha M., Viode A., Kanarek N., Petrova B., Zhao Y., Boddapati A., Tharp G., Pellegrini K., Beagle E., Cowan D., Hamilton S., Ribeiro S., Hodder T., Lee S., Wilson M., Alvarenga B., Rajan J., Schroeder A., Tsitsiklis A., Mick E., Guerrero Y., Love C., Maliskova L., Adkisson M., Siles N., Geltman J., Hurley K., Saksena M., Altman D., Srivastava K., Eaker L., Bermúdez-González M., Beach K., Sominsky L., Azad A., Mulder L., Kleiner G., Lee A., Do E., Fernandes A., Manohar M., Hagan T., Blish C., Din H., Roque J., Yang S., Sigal N., Chang I., Tribout H., Harris P., Consolo M., Connors J., Bernui M., Kutzler M., Edwards C., Lee E., Lin E., Croen B., Semenza N., Rogowski B., Melnyk N., Woloszczuk K., Cusimano G., Bell M., Furukawa S., McLin R., Schearer P., Sheidy J., Tegos G., Nagle C., Smolen K., Desjardins M., van Haren S., Mitre X., Cauley J., Li X., Tong A., Evans B., Montesano C., Licona J., Krauss J., Chang J., Izaguirre N., Rooks R., Elashoff D., Brook J., Ramires-Sanchez E., Llamas M., Rivera A., Perdomo C., Ward D., Magyar C., Fulcher J., Pickering H., Sen S., Chaudhary O., Coppi A., Fournier J., Mohanty S., Muenker M., Nelson A., Raddassi K., Rainone M., Ruff W., Salahuddin S., Schulz W., Vijayakumar P., Wang H., Wunder E., Young H., Rothman J., Konstorum A., Chen E., Cotsapas C., Grubaugh N., Wang X., Xu L., Asashima H., Bristow L., Hussaini L., Hellmeister K., Wimalasena S., Cheng A., Spainhour C., Scherer E., Johnson B., Bechnak A., Ciric C., Hewitt L., Carter E., Mcnair N., Panganiban B., Huerta C., Usher J., Vaysman T., Holland S., Abe-Jones Y., Asthana S., Beagle A., Bhide S., Carrillo S., Chak S., Ghale R., Gonzalez A., Jauregui A., Jones N., Lea T., Lee D., Lota R., Milush J., Nguyen V., Pierce L., Prasad P., Rao A., Samad B., Shaw C., Sigman A., Sinha P., Ward A., Willmore A., Zhan J., Rashid S., Rodriguez N., Tang K., Altamirano L., Betancourt L., Curiel C., Sutter N., Paz M., Tietje-Ulrich G., Leroux C., Thakur N., Vasquez J., Santhosh L., Song L., Nelson E., Moldawer L., Borresen B., Roth-Manning B., Ungaro R., Oberhaus J., Booth J., Sinko L., Brunton A., Sullivan P., Strnad M., Lyski Z., Coulter F., Micheleti C., Conway M., Francisco D., Molzahn A., Erickson H., Wilson C., Schunk R., Sierra B., Hughes T., Peters B., Kleinstein S., Reed E., Augustine A., Diray-Arce J., Maecker H., Altman M., Montgomery R., Becker P., Rouphael N.,

Disease areaApplication areaSample typeProducts
Infectious Diseases
Pathophysiology
Patient Stratification
Serum
Olink Target 96

Olink Target 96

Abstract

Post-acute sequelae of SARS-CoV-2 (PASC) is a significant public health concern. We describe Patient Reported Outcomes (PROs) on 590 participants prospectively assessed from hospital admission for COVID-19 through one year after discharge. Modeling identified 4 PRO clusters based on reported deficits (minimal, physical, mental/cognitive, and multidomain), supporting heterogenous clinical presentations in PASC, with sub-phenotypes associated with female sex and distinctive comorbidities. During the acute phase of disease, a higher respiratory SARS-CoV-2 viral burden and lower Receptor Binding Domain and Spike antibody titers were associated with both the physical predominant and the multidomain deficit clusters. A lower frequency of circulating B lymphocytes by mass cytometry (CyTOF) was observed in the multidomain deficit cluster. Circulating fibroblast growth factor 21 (FGF21) was significantly elevated in the mental/cognitive predominant and the multidomain clusters. Future efforts to link PASC to acute anti-viral host responses may help to better target treatment and prevention of PASC.

Read publication ↗